Iberdomide

Generic Name: Iberdomide

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₂₇N_₃O_₅

CAS Number: 1323403-33-3

Unique Ingredient Identifier: 8V66F27X44

Background: Iberdomide (CC-220) has been used in trials studying the treatment of Systemic Lupus Erythematosus.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients

Phase 2

Recruiting

Conditions: Multiple Myeloma

First Posted Date: 2022-03-09

Last Posted Date: 2024-12-12

Lead Sponsor: Canadian Myeloma Research Group

Target Recruit Count: 75

Registration Number: NCT05272826

Locations: 🇨🇦
London Health Sciences Centre, London, Ontario, Canada

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

Phase 1

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Iberdomide
Drug: Oral Dexamethasone

First Posted Date: 2022-01-20

Last Posted Date: 2024-08-22

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 66

Registration Number: NCT05199311

Locations: 🇺🇸
Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸
John Theurer Cancer Center, Hackensack, New Jersey, United States

Iberdomide Maintenance Therapy in Patients With Multiple Myeloma

Phase 2

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Iberdomide

First Posted Date: 2022-01-04

Last Posted Date: 2024-10-11

Lead Sponsor: University of Nebraska

Target Recruit Count: 42

Registration Number: NCT05177536

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Phase 1

Recruiting

Conditions: Non-Hodgkin Lymphoma

Interventions: Drug: SC Mosunetuzumab
Drug: IV Glofitamab
Drug: Iberdomide
Drug: Golcadomide
Drug: Obinutuzumab
Drug: Tocilizumab

First Posted Date: 2021-12-27

Last Posted Date: 2024-12-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 121

Registration Number: NCT05169515

Locations: 🇺🇸
UCSF/Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program, San Francisco, California, United States
🇮🇹
Irccs Ospedale San Raffaele;U.O. Oculistica, Milano, Lombardia, Italy
🇪🇸
Hospital General Universitario Gregorio Maranon, Madrid, Spain

and more 24 locations

A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma at First Relapse

Interventions: Drug: Ixazomib
Drug: Iberdomide
Drug: Dexamethasone Oral

First Posted Date: 2021-08-10

Last Posted Date: 2023-05-30

Lead Sponsor: Nantes University Hospital

Target Recruit Count: 80

Registration Number: NCT04998786

Locations: 🇫🇷
CHR, Annecy, France
🇫🇷
CHU Henri Mondor, Paris, France
🇫🇷
CHRU, Rennes, France

and more 13 locations

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Dexamethasone
Drug: Daratumumab
Drug: Bortezomib
Drug: Iberdomide

First Posted Date: 2021-07-26

Last Posted Date: 2024-12-04

Lead Sponsor: Celgene

Target Recruit Count: 864

Registration Number: NCT04975997

Locations: 🇺🇸
Ohio Health Corporation, Columbus, Ohio, United States
🇺🇸
MetroHealth Medical Center - Main Campus, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic - Taussig Cancer Institute, Cleveland, Ohio, United States

and more 279 locations

Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function

Phase 1

Completed

Conditions: Renal Insufficiency

Interventions: Drug: Iberdomide

First Posted Date: 2021-06-22

Last Posted Date: 2023-02-15

Lead Sponsor: Celgene

Target Recruit Count: 26

Registration Number: NCT04933747

Locations: 🇺🇸
Local Institution - 002, Knoxville, Tennessee, United States
🇺🇸
Local Institution - 003, San Antonio, Texas, United States
🇺🇸
Local Institution - 001, Orlando, Florida, United States

Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Iberdomide

First Posted Date: 2020-09-25

Last Posted Date: 2024-03-06

Lead Sponsor: Stichting European Myeloma Network

Target Recruit Count: 160

Registration Number: NCT04564703

Locations: 🇬🇷
Alexandra General Hospital -Department of Clinical Therapeutics N.K. Univ. of Athens, Athens, Greece
🇫🇷
CHU Hôtel-Dieu, 1, place Alexis Ricordeau, 44093 NANTES Cedex 1, FRANCE, Nantes, France
🇮🇹
Ospedale Generale Regionale-Divisione di Ematologia e Centro Trapianto Midollo Osseo, Bolzano, Italy

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy